HRP20151200T1 - Metoda za snižavanje intraokularnog tlaka kod ljudi - Google Patents

Metoda za snižavanje intraokularnog tlaka kod ljudi Download PDF

Info

Publication number
HRP20151200T1
HRP20151200T1 HRP20151200TT HRP20151200T HRP20151200T1 HR P20151200 T1 HRP20151200 T1 HR P20151200T1 HR P20151200T T HRP20151200T T HR P20151200TT HR P20151200 T HRP20151200 T HR P20151200T HR P20151200 T1 HRP20151200 T1 HR P20151200T1
Authority
HR
Croatia
Prior art keywords
substance
use according
pharmaceutical composition
glaucoma
iop
Prior art date
Application number
HRP20151200TT
Other languages
English (en)
Croatian (hr)
Inventor
Shikha Barman
Rudolf A. Baumgartner
Original Assignee
Inotek Pharmaceuticals Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43030847&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20151200(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inotek Pharmaceuticals Corporation filed Critical Inotek Pharmaceuticals Corporation
Publication of HRP20151200T1 publication Critical patent/HRP20151200T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Prostheses (AREA)
HRP20151200TT 2009-05-01 2010-04-30 Metoda za snižavanje intraokularnog tlaka kod ljudi HRP20151200T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17465509P 2009-05-01 2009-05-01
US21999009P 2009-06-24 2009-06-24
EP10770402.5A EP2424546B1 (en) 2009-05-01 2010-04-30 Method of reducing intraocular pressure in humans
PCT/US2010/033112 WO2010127210A1 (en) 2009-05-01 2010-04-30 Method of reducing intraocular pressure in humans

Publications (1)

Publication Number Publication Date
HRP20151200T1 true HRP20151200T1 (hr) 2016-01-15

Family

ID=43030847

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20151200TT HRP20151200T1 (hr) 2009-05-01 2010-04-30 Metoda za snižavanje intraokularnog tlaka kod ljudi

Country Status (25)

Country Link
US (2) US8470800B2 (https=)
EP (1) EP2424546B1 (https=)
JP (1) JP5778663B2 (https=)
KR (1) KR101757940B1 (https=)
CN (1) CN102413832B (https=)
AU (1) AU2010242943B2 (https=)
BR (1) BRPI1009971A2 (https=)
CA (1) CA2762064A1 (https=)
CL (1) CL2011002675A1 (https=)
DK (1) DK2424546T3 (https=)
EA (1) EA024042B1 (https=)
ES (1) ES2554684T3 (https=)
HR (1) HRP20151200T1 (https=)
HU (1) HUE028068T2 (https=)
IL (1) IL216081A (https=)
MX (1) MX2011011229A (https=)
MY (1) MY159244A (https=)
NZ (1) NZ596428A (https=)
PL (1) PL2424546T3 (https=)
PT (1) PT2424546E (https=)
RS (1) RS54378B1 (https=)
SG (1) SG175346A1 (https=)
SI (1) SI2424546T1 (https=)
SM (1) SMT201500295B (https=)
WO (1) WO2010127210A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008062567A1 (de) 2008-12-16 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Dipeptoid-Prodrugs und ihre Verwendung
DE102009006602A1 (de) * 2009-01-29 2010-08-05 Bayer Schering Pharma Aktiengesellschaft Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
WO2011053569A1 (en) * 2009-10-26 2011-05-05 Inotek Pharmaceuticals Corporation Ophthalmic formulation and method of manufacture thereof
LT2523669T (lt) * 2010-01-11 2017-04-25 Inotek Pharmaceuticals Corporation Akispūdžio mažinimo būdas, derinys ir rinkinys
US8455457B2 (en) * 2010-03-19 2013-06-04 Inotek Pharmaceuticals Corporation Combination compositions for reducing intraocular pressure
JP2013522322A (ja) * 2010-03-19 2013-06-13 イノテック ファーマシューティカルズ コーポレイション 眼内圧を下げるためのアデノシンａ１受容体アゴニストと炭酸脱水酵素阻害剤との組合せ組成物
PH12012501906A1 (en) * 2010-03-26 2013-01-14 Inotek Pharmaceuticals Corp Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof
DE102010030688A1 (de) 2010-06-30 2012-01-05 Bayer Schering Pharma Aktiengesellschaft Substituierte Dicyanopyridine und ihre Verwendung
US20120058983A1 (en) * 2010-09-02 2012-03-08 Bayer Pharma Aktiengesellschaft Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
PT2807178T (pt) 2012-01-26 2017-08-08 Inotek Pharmaceuticals Corp Polimorfos anidros de nitrato de (2r,3s,4r,5r)-5-(6-(ciclopentilamino)-9h-purin-9-il)-3,4-dihidroxitetrahidrofuran-2-il)}metilo e seus processos de preparação
NZ630759A (en) 2013-03-15 2017-07-28 Inotek Pharmaceuticals Corp Ophthalmic formulations comprising an a1 agonist
WO2016090005A1 (en) * 2014-12-03 2016-06-09 Inotek Pharmaceuticals Corporation Methods of preventing, reducing or treating macular degeneration

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103087133B (zh) * 2004-05-26 2016-09-14 伊诺泰克制药公司 嘌呤衍生物作为腺苷a1受体激动剂及其用法
CN101010085B (zh) * 2004-05-26 2012-12-26 伊诺泰克制药公司 嘌呤衍生物作为腺苷a1受体激动剂及其用法
EA015683B1 (ru) * 2005-11-30 2011-10-31 Инотек Фармасьютикалз Корпорейшн Производные пурина и способы их применения
WO2011053569A1 (en) * 2009-10-26 2011-05-05 Inotek Pharmaceuticals Corporation Ophthalmic formulation and method of manufacture thereof
LT2523669T (lt) * 2010-01-11 2017-04-25 Inotek Pharmaceuticals Corporation Akispūdžio mažinimo būdas, derinys ir rinkinys
US8455457B2 (en) * 2010-03-19 2013-06-04 Inotek Pharmaceuticals Corporation Combination compositions for reducing intraocular pressure
JP2013522322A (ja) * 2010-03-19 2013-06-13 イノテック ファーマシューティカルズ コーポレイション 眼内圧を下げるためのアデノシンａ１受容体アゴニストと炭酸脱水酵素阻害剤との組合せ組成物

Also Published As

Publication number Publication date
HUE028068T2 (en) 2016-11-28
JP5778663B2 (ja) 2015-09-16
WO2010127210A1 (en) 2010-11-04
MX2011011229A (es) 2011-11-18
SG175346A1 (en) 2011-11-28
EP2424546B1 (en) 2015-10-28
KR101757940B1 (ko) 2017-07-13
NZ596428A (en) 2014-03-28
CN102413832B (zh) 2015-11-25
KR20120017026A (ko) 2012-02-27
SI2424546T1 (sl) 2016-02-29
US20100279970A1 (en) 2010-11-04
US20130217643A1 (en) 2013-08-22
CL2011002675A1 (es) 2012-06-01
EP2424546A4 (en) 2013-01-23
PT2424546E (pt) 2015-12-23
ES2554684T3 (es) 2015-12-22
PL2424546T3 (pl) 2016-04-29
EA201171339A1 (ru) 2012-05-30
CN102413832A (zh) 2012-04-11
AU2010242943A1 (en) 2011-12-01
IL216081A (en) 2015-11-30
HK1167599A1 (en) 2012-12-07
CA2762064A1 (en) 2010-11-04
JP2012525437A (ja) 2012-10-22
EA024042B1 (ru) 2016-08-31
IL216081A0 (en) 2012-01-31
DK2424546T3 (en) 2015-12-14
US8470800B2 (en) 2013-06-25
MY159244A (en) 2016-12-30
BRPI1009971A2 (pt) 2016-03-15
RS54378B1 (sr) 2016-04-28
SMT201500295B (it) 2016-01-08
EP2424546A1 (en) 2012-03-07
AU2010242943B2 (en) 2016-09-29

Similar Documents

Publication Publication Date Title
HRP20151200T1 (hr) Metoda za snižavanje intraokularnog tlaka kod ljudi
AU2011282681B2 (en) Preservative free bimatoprost and timolol solutions
KR20100135748A (ko) 아쥬반트로서의 안과용 ｎｓａｉｄ
AU2023208076A1 (en) Fixed dose combination of brimonidine and timolo
CA3026053A1 (en) Treatment of dry eye disease with parasympathetic and anti-sympathetic agents
Aptel et al. Intraocular pressure-lowering combination therapies with prostaglandin analogues
JP7355539B2 (ja) 眼科組成物
HRP20170007T1 (hr) Kombinacija, komplet i metoda za smanjivanje intraokularnog tlaka
CA3081593A1 (en) Pharmaceutical compositions for controlling and/or reducing the progression of myopia
CA3073718A1 (en) Ocular pharmaceutical compositions
HRP20170009T1 (hr) Kombinacija sastava agonista adenozina a1 i neselektivnih blokatora beta adrenergičkih receptora za smanjivanje intraokularnog tlaka
Simmons et al. Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension
ES2764654T3 (es) Combinaciones de prostaglandinas y donantes de óxido nítrico
Lindén Therapeutic potential of prostaglandin analogues in glaucoma
JP2012250951A (ja) アデノシン誘導体とプロスタグランジン類とβ受容体遮断薬の組合せ剤
JPWO2006098292A1 (ja) 眼疾患治療剤
JP2012250949A (ja) アデノシン誘導体と炭酸脱水酵素阻害剤とβ受容体遮断薬の組合せ剤
JP2012250953A (ja) アデノシン誘導体とα２受容体作動薬の組合せ剤
WO2019124523A1 (ja) ＦＰ作動薬とβ遮断薬を含有する緑内障治療剤
JP2012250947A (ja) アデノシン誘導体とβ受容体遮断薬の組合せ剤
KR20130108376A (ko) 신경 보호 작용을 갖는 약제 배합
JP2012250950A (ja) アデノシン誘導体とプロスタグランジン類の組合せ剤
JP2016034936A (ja) 角膜上皮障害治療剤の組み合わせ
HK40039952A (en) Pharmaceutical compositions for controlling and/or reducing the progression of myopia
Rocha-Sousa et al. Journal of Clinical & Experimental Ophthalmology